Company: TDBCP
Filing Date: 2025-04-03
Form Type: 424B3
Source: 0001140361-25-012065
Chunk: 1

Company: TORONTO DOMINION BANK
Filing Date: 2025-04-03
Form: 424B3
Chunk 1
---
, including the specific Market Measure, the Capped Value, and certain risk factors.  The 
 applicable term sheet will identify, if applicable, any additions or changes to the terms specified in this product supplement.                                                                                  |

| • | ARNs will be issued in denominations of whole units.Unless otherwise set forth in the applicable term sheet, each unit will have a principal amount of $10.The applicable term sheet may also 
 set forth a minimum number of units that you must purchase.                                                                                                                                   |

| • | Unless otherwise specified in the applicable term sheet, ARNs will not be listed on a securities exchange or quotation system. |

| • | BofA Securities, Inc. (“BofAS”) and one or more of its affiliates and TD Securities (USA)           
 LLC (“TDS”) may act as our agents to offer ARNs, and will act in a principal capacity in such role. |

ARNs are senior unsecured debt securities issued by TD, are not guaranteed or insured by the Canada Deposit Insurance Corporation (the “ CDIC”), the U.S. Federal Deposit Insurance Corporation (the “ FDIC”) or any other governmental agency or instrumentality of any jurisdiction, and are not, either directly or indirectly, an obligation of any third party. ARNs have complex features and investing in ARNs involves risks not associated with an investment in conventional debt securities. Potential purchasers of ARNs should consider the information in “Risk Factors” beginning on page PS-6 of this product supplement and page 1 of the accompanying prospectus. You may lose some or all of your investment in ARNs. None of the U.S. Securities and Exchange Commission (the “ SEC”), any state securities commission, or any other regulatory body has approved or disapproved of these securities or passed upon the adequacy or accuracy of this product supplement or the accompanying prospectus. Any representation to the contrary is a criminal offense. BofA Securities TABLE OF CONTENTS

|                                                           | Page  |
| SUMMARY                                                   | PS-3  |
| RISK FACTORS                                              | PS-6  |
| USE OF PROCEEDS AND HEDGING                               | PS-17 |
| DESCRIPTION OF ARNS                                       | PS-18 |
| SUPPLEMENTAL PLAN OF DISTRIBUTION (CONFLICTS OF INTEREST) | PS-30 |
| SUPPLEMENTAL DISCUSSION OF CANADIAN TAX CONSEQUENCES      | PS-32 |
| MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES             | PS-33 |
| ER